Menu Search
Equities

Inhalerx Ltd

IRX:ASX

Inhalerx Ltd

Actions
Health CareMedical Equipment and Services
  • Price (AUD)0.038
  • Today's Change0.008 / 26.67%
  • Shares traded590.00k
  • 1 Year change-2.56%
  • Beta-1.0469
Data delayed at least 20 minutes, as of Nov 15 2024 03:07 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in AUDIncome statement in AUDView more

Year on year Inhalerx Ltd grew revenues 2,226.09% from 51.85k to 1.21m while net income improved from a loss of 1.93m to a smaller loss of 1.44m.
Gross margin--
Net profit margin-84.88%
Operating margin-78.13%
Return on assets-88.94%
Return on equity-252.24%
Return on investment-252.07%
More ▼

Cash flow in AUDView more

In 2023, cash reserves at Inhalerx Ltd fell by 1.42m. Cash Flow from Financing totalled 544.29k or 45.13% of revenues. In addition the company used 1.96m for operations while cash from investing was breakeven.
Cash flow per share-0.0001
Price/Cash flow per share--
Book value per share-0.0003
Tangible book value per share-0.0003
More ▼

Balance sheet in AUDView more

Inhalerx Ltd has a Debt to Total Capital ratio of 119.50%.
Current ratio0.9185
Quick ratio--
Total debt/total equity--
Total debt/total capital1.19
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.